Nexalin Technology (NXL) announced the publication of an independent, peer-reviewed study in The American Journal on Addictions titled “High-intensity transcranial alternating current stimulation for gambling disorder comorbidities with alcohol use disorders: A case report.” The study evaluated the safety and efficacy of Nexalin’s 15 milliamp, mA, neurostimulation device in a patient diagnosed with both gambling disorder and alcohol use disorder. Following 20 outpatient treatment sessions over 10 days, the patient achieved complete abstinence from gambling and alcohol, along with marked improvement in cognitive control and no adverse effects during a three-month follow-up period.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Nexalin Technology Faces Financial Risks Amid U.S.-China Trade Tensions
- Nexalin Technology appoints Carmi Masha as exclusive distributor in Israel
- Nexalin Technology announces FDA acceptance of Q-Sub for Gen-2 SYNC
- Nexalin Technology announces regulatory approval to sell Gen 2 SYNC
- Nexalin announces three studies published on Gen-2 Nexalin DIFS technology